<DOC>
	<DOC>NCT01799824</DOC>
	<brief_summary>The purpose of this study is to confirm the effect of ANT-1403 in the treatment of primary axillary hyperhidrosis.</brief_summary>
	<brief_title>Clinical Trial to Evaluate ANT-1403 in the Treatment of Primary Axillary Hyperhidrosis</brief_title>
	<detailed_description />
	<mesh_term>Hyperhidrosis</mesh_term>
	<criteria>ages 18 70 years of age diagnosis of moderate to severe primary axillary hyperhidrosis ≥50 mg of sweat production/axilla in 5 minutes as measured gravimetrically HDSS score of ≥3 diagnosis of secondary hyperhidrosis skin affliction in the axilla requiring medical treatment 20% aluminum hydrochloride, e.g. Drysol®, in 2 weeks prior of Baseline oral anticholinergic treatment botulinum toxin treatment in the prior 9 months history of surgery for axillary hyperhidrosis present or history of neuromuscular disease female subjects who are pregnant or are nursing a child</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>